Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 223

Next Previous
Drug Profile

GB 223

Alternative Names: GB223

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Developer Genor Biopharma; The Fifth Affiliated Hospital of Guangzhou Medical University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Giant cell tumour of bone; Postmenopausal osteoporosis

Most Recent Events

  • 12 Feb 2025 GB 223 is still in phase I trials for Giant cell tumour of bone and Postmenopausal osteoporosis (In volunteers) (In volunteers) in China (Parental) (Genor Biopharma pipeline, February 2025)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Giant-cell-tumour-of-bone(In volunteers) in China (Parenteral, Injection)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Postmenopausal-osteoporosis(In volunteers) in China (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top